LRP6 and neoplasm: The combined treatment with vismodegib and the anti-LRP6 antibody, which is the most important co-receptor of Wnt in BCC, led to a 33% of tumor decrease in a murine model compared to the monotherapy with vismodegib: the combined therapy was effective also in the delay of tumor regrowth after therapy discontinuation [52].